World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
35519
World Ranking
10798
National Ranking
5557

Overview

Naval Daver is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the field of Medicine, with significant contributions in subfields including Hematology, Molecular Biology, Genetics, Oncology, and Public Health, Environmental and Occupational Health.

The scientist's work covers a range of topics focused heavily on leukemia and related hematologic conditions. Main topics of their research include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Histone Deacetylase Inhibitors Research
  • Protein Degradation and Inhibitors

Naval Daver has co-authored extensively with several prominent collaborators. Frequent co-authors include:

  • Tapan M. Kadia
  • Courtney D. DiNardo
  • Farhad Ravandi
  • Hagop M. Kantarjian
  • Guillermo Garcia-Manero

The scientist's publications appear in well-known medical and oncology journals. Frequent publication venues include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • American Journal of Hematology
  • Journal of Clinical Oncology
  • Cancer

Naval Daver's recent papers illustrate a focus on acute myeloid leukemia and therapeutic advancements. Selected recent publications include:

  • Acute myeloid leukemia: current progress and future directions (2021), Blood Cancer Journal
  • MDM2 inhibition: an important step forward in cancer therapy (2020), Leukemia
  • Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials (2023), Nature Medicine
  • Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia (2021), Journal of Clinical Oncology
  • 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial (2020), The Lancet Haematology

Best Publications

  • Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

    Sattva S. Neelapu;Sudhakar Tummala;Partow Kebriaei;William Wierda

  • An inhibitor of oxidative phosphorylation exploits cancer vulnerability.

    Jennifer R. Molina;Yuting Sun;Marina Protopopova;Sonal Gera

  • Targeting FLT3 mutations in AML: review of current knowledge and evidence.

    Naval Daver;Richard F. Schlenk;Nigel H. Russell;Mark J. Levis

  • Acute myeloid leukemia: current progress and future directions.

    Hagop Kantarjian;Tapan Kadia;Courtney DiNardo;Naval Daver

  • Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.

    Naval Daver;Guillermo Garcia-Manero;Sreyashi Basu;Prajwal C Boddu

  • Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

    Courtney D. DiNardo;Caitlin R. Rausch;Christopher Benton;Tapan Kadia

  • Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

    Farhad Ravandi;Mona Lisa Alattar;Michael R. Grunwald;Michelle A. Rudek

  • Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

    Jean Pierre J Issa;Jean Pierre J Issa;Gail Roboz;David Rizzieri;Elias Joseph Jabbour

  • Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

    Koji Sasaki;Koji Sasaki;Sara S Strom;Susan O'Brien;Elias Jabbour

  • Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A single-centre, phase 2 study

    Elias Jabbour;Hagop Kantarjian;Farhad Ravandi;Deborah Thomas

  • MDM2 inhibition: an important step forward in cancer therapy

    Marina Konopleva;Giovanni Martinelli;Naval Daver;Cristina Papayannidis

  • Long-term outcome of acute promyelocytic leukemia treated with all- trans-retinoic acid, arsenic trioxide, and gemtuzumab

    Yasmin Abaza;Hagop M. Kantarjian;Guillermo Garcia-Manero;Elihu Estey

  • The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

    Patrick Williams;Sreyashi Basu;Guillermo Garcia-Manero;Christopher S. Hourigan

  • Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

    Nicholas J. Short;Marina Konopleva;Tapan M. Kadia;Gautam Borthakur

  • 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

    Courtney D DiNardo;Abhishek Maiti;Caitlin R Rausch;Naveen Pemmaraju

  • Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

    Elias Jabbour;Nicholas J Short;Farhad Ravandi;Xuelin Huang

  • Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

    Naval Daver;Deborah Thomas;Farhad Ravandi;Jorge Cortes

  • Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

    Hagop Kantarjian;Farhad Ravandi;Nicholas J Short;Xuelin Huang

  • TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.

    Tapan M. Kadia;DM Preetesh Jain Md;Farhad Ravandi;Guillermo Garcia-Manero

  • Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.

    Kate J. Newberry;Keyur Patel;Lucia Masarova;Rajyalakshmi Luthra

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Marina Konopleva
Marina Konopleva The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Sherry Pierce
Sherry Pierce The University of Texas MD Anderson Cancer Center
Nitin Jain
Nitin Jain The University of Texas MD Anderson Cancer Center
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine but seeking flexible or alternative pathways, online healthcare degrees offer a range of accessible options. Pursuing a career in nursing is a popular choice, with nursing school online programs allowing students to balance studies with other commitments. These accredited programs provide a solid foundation in patient care and healthcare systems.

Existing registered nurses can advance their qualifications through rn to bsn online programs. These bridge programs are designed to enhance leadership skills and open doors to advanced nursing roles. For non-nurses aiming to enter the field, direct entry msn programs online offer an accelerated route to a master's degree and licensure.

Nurses interested in leadership, academia, or research can further their education with an online phd nursing degree. These programs enable working professionals to reach the highest levels of nursing practice, often without having to relocate or leave their jobs. Exploring these online pathways can lead to rewarding and impactful healthcare careers.

Best Scientists Citing Naval Daver

Trending Scientists

Recently Published Articles